FR-167356
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss.
For research use only. We do not sell to patients.
- CAS No.: 174185-16-1
- Formula: C19H17Cl2NO3
- Molecular Weight:378.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
FR-167356 (200 mg/kg; p.o.; daily, for 10 days; male C57BL/6 mice with B16-F10 xenografts) reduces bone metastasis compared to untreated group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:male C57BL/6 mice with B16-F10 xenografts[1]
-
Dosage:200 mg/kg
-
Administration:Oral administration; daily, for 10 days
-
Result:Reduced the expression of MMP9 and reduced bone metastasis.
Chemical Information
-
CAS No. 174185-16-1
-
Molecular Weight 378.25
-
Formula C19H17Cl2NO3
-
SMILES
O=C(NC1=C(OC(C)=C2C(C)(O)C)C2=CC=C1)C3=C(Cl)C=CC=C3Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Nishisho T, et, al. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55. [Content Brief]
[2]. Niikura K, et, al. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)